CLV IntelligenceReimbursement Policy Monitoring

Code intelligence

C83.39 reimbursement alerts

Policy changes, MAC LCD updates, and CMS guidance matched to code C83.39.

Normal code riskView ICD-10 detail

Signal breakdown

2 shown · 2 total in platform

Risk: Normal
0

Critical

0%

0

High

0%

2

Routine

100%

0

Low

0%

New this month

—

alerts added in last 30 days

Effective soon

—

no upcoming deadlines

LCD L39513: Allogeneic Hematopoietic Cell Transplantation for Primary Refractory or Relapsed Hodgkin and Non-Hodgkin Lymphoma with B-cell or T-cell Origin — Wellpoint Federal

Policy LCD-L39513 · Oncology

Routine

Allo-HCT coverage rules for relapsed/refractory Hodgkin & NHL now active.

View alert

LCD L39297: Off-label Use of Rituximab and Rituximab Biosimilars — NGS

Policy LCD-L39297 · Oncology

Routine

Off-label Rituximab use may impact Medicare billing.

View alert

Audit documentation

Building an audit file that includes C83.39?

The Tripwire Audit Pack exports 12 months of Oncology policy-change history — every alert with a link to its government source document, as a formatted PDF for compliance distribution plus a machine-readable CSV. Delivered automatically after payment. No account, no call.

Get the Oncology audit pack — $349One-time purchase · not a subscription